[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609678":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":286,"collaborators":11,"id":288,"slug":289,"hasResults":290,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":290,"sex":296,"minAge":297,"maxAge":11,"enrollmentInfo":298,"targetDuration":11,"studyType":301,"phases":302,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":325},{"fullName":5,"class":6},"SOFIE","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with gastric or esophageal cancer receiving [18F]FAPI-74","EXPERIMENTAL",null,[13],"Drug: [18F]FAPI-74 PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","[18F]FAPI-74 PET\u002FCT","\\[18F\\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastric or esophageal cancers.",[9],[21],{"name":22,"affiliation":5,"role":23},"Sherly Mosessian, Ph.D","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Alex Osipova","CONTACT","1-800-753-5368","Alex.osipova@sofie.com",{"name":31,"role":27,"phone":28,"phoneExt":11,"email":32},"Bridget Adams","bridget.adams@sofie.com",[34,59,75,91,107,123,140,157,174,190,207,224,237,254,269],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Helios CR Inc.\u002FRadNet","RECRUITING","Cerritos","California","90703","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-118.06479,33.85835,{"lat":46,"lon":45},[49,53,56],{"name":50,"role":27,"phone":51,"phoneExt":11,"email":52},"Sabrina Mora","562-693-4477","Sabrina.mora@heliosclinical.com",{"name":54,"role":27,"phone":11,"phoneExt":11,"email":55},"Alexis Velasco","alexis.velasco@heliosclinical.com",{"name":57,"role":58,"phone":11,"phoneExt":11,"email":11},"Omkar Marathe, M.D.","PRINCIPAL_INVESTIGATOR",{"facility":60,"status":36,"city":61,"state":38,"zip":62,"country":40,"countryCode":41,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"City of Hope National Cancer Center","Duarte","91010",{"type":43,"coordinates":64},[65,66],-117.97729,34.13945,{"lat":66,"lon":65},[69,73],{"name":70,"role":27,"phone":71,"phoneExt":11,"email":72},"Miranda Qian","(626) 218-3533","lqian@coh.org",{"name":74,"role":58,"phone":11,"phoneExt":11,"email":11},"Dani Castillo, M.D.",{"facility":76,"status":36,"city":77,"state":38,"zip":78,"country":40,"countryCode":41,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Hoag Memorial Hospital","Irvine","92618",{"type":43,"coordinates":80},[81,82],-117.82311,33.66946,{"lat":82,"lon":81},[85,89],{"name":86,"role":27,"phone":87,"phoneExt":11,"email":88},"Beth Thomsen","949-557-0285","Beth.thomsen@hoag.org",{"name":90,"role":58,"phone":11,"phoneExt":11,"email":11},"Gary Ulaner, MD",{"facility":92,"status":36,"city":93,"state":38,"zip":94,"country":40,"countryCode":41,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"UCLA","Los Angeles","90095",{"type":43,"coordinates":96},[97,98],-118.24368,34.05223,{"lat":98,"lon":97},[101,105],{"name":102,"role":27,"phone":103,"phoneExt":11,"email":104},"Steven Stokes","310 206-7436","SStokes@mednet.ucla.edu",{"name":106,"role":58,"phone":11,"phoneExt":11,"email":11},"Mark Girgis, MD",{"facility":108,"status":36,"city":109,"state":38,"zip":110,"country":40,"countryCode":41,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Stanford University","Stanford","94305",{"type":43,"coordinates":112},[113,114],-122.16608,37.42411,{"lat":114,"lon":113},[117,121],{"name":118,"role":27,"phone":119,"phoneExt":11,"email":120},"Kavin Tamizhmani","(650)-497-6046","ktamizhm@stanford.edu",{"name":122,"role":58,"phone":11,"phoneExt":11,"email":11},"Matteo Novello, MD",{"facility":124,"status":36,"city":125,"state":126,"zip":127,"country":40,"countryCode":41,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Moffit Cancer Center","Tampa","Florida","33612",{"type":43,"coordinates":129},[130,131],-82.45843,27.94752,{"lat":131,"lon":130},[134,138],{"name":135,"role":27,"phone":136,"phoneExt":11,"email":137},"Jacqueline Guillermo Adams","813-745-2468","Jacqueline.GuillermoAdams@moffitt.org",{"name":139,"role":58,"phone":11,"phoneExt":11,"email":11},"Ghassan El-Haddad, MD",{"facility":141,"status":36,"city":142,"state":143,"zip":144,"country":40,"countryCode":41,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Indiana University Health University Hospital","Indianapolis","Indiana","46202",{"type":43,"coordinates":146},[147,148],-86.15804,39.76838,{"lat":148,"lon":147},[151,155],{"name":152,"role":27,"phone":153,"phoneExt":11,"email":154},"Eric Grubbs","(317) 274-2584","eegrubbs@iu.edu",{"name":156,"role":58,"phone":11,"phoneExt":11,"email":11},"Cindy Yuan, MD PhD",{"facility":158,"status":36,"city":159,"state":160,"zip":161,"country":40,"countryCode":41,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":43,"coordinates":163},[164,165],-71.05977,42.35843,{"lat":165,"lon":164},[168,172],{"name":169,"role":27,"phone":170,"phoneExt":11,"email":171},"Isabelle Lin","617-643-6837","ilin4@mgh.harvard.edu",{"name":173,"role":58,"phone":11,"phoneExt":11,"email":11},"Shadi Esfahani, MD",{"facility":175,"status":36,"city":176,"state":160,"zip":177,"country":40,"countryCode":41,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"UMass\u002FShields","Worcester","01655",{"type":43,"coordinates":179},[180,181],-71.80229,42.26259,{"lat":181,"lon":180},[184,188],{"name":185,"role":27,"phone":186,"phoneExt":11,"email":187},"Sara Schiller","774-548-1090","Sara.Schiller1@umassmed.edu",{"name":189,"role":58,"phone":11,"phoneExt":11,"email":11},"Elisa Franquet-Elia, MD",{"facility":191,"status":36,"city":192,"state":193,"zip":194,"country":40,"countryCode":41,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"Mayo Clinic Rochester","Rochester","Minnesota","55905",{"type":43,"coordinates":196},[197,198],-92.4699,44.02163,{"lat":198,"lon":197},[201,205],{"name":202,"role":27,"phone":203,"phoneExt":11,"email":204},"Kera Delaney","507-293-2227","delaney.kera@mayo.edu",{"name":206,"role":58,"phone":11,"phoneExt":11,"email":11},"Ajit H Goenka, MD",{"facility":208,"status":209,"city":210,"state":210,"zip":211,"country":40,"countryCode":41,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"Icahn School of Medicine at Mount Sinai","NOT_YET_RECRUITING","New York","10029",{"type":43,"coordinates":213},[214,215],-74.00597,40.71427,{"lat":215,"lon":214},[218,222],{"name":219,"role":27,"phone":220,"phoneExt":11,"email":221},"Ilda Bander","212-241-0763","Ilda.bander@mountsinai.org",{"name":223,"role":58,"phone":11,"phoneExt":11,"email":11},"Sampanna Rayamajhi, MD",{"facility":225,"status":36,"city":210,"state":210,"zip":226,"country":40,"countryCode":41,"cosmosGeoPoint":227,"geoPoint":229,"contacts":230},"Memorial Sloan Kettering Cancer Center","10065",{"type":43,"coordinates":228},[214,215],{"lat":215,"lon":214},[231,235],{"name":232,"role":27,"phone":233,"phoneExt":11,"email":234},"Jordayna Francois","(646)888-6819","francoij@mskcc.org",{"name":236,"role":58,"phone":11,"phoneExt":11,"email":11},"Aria Razmari, MD",{"facility":238,"status":36,"city":239,"state":240,"zip":241,"country":40,"countryCode":41,"cosmosGeoPoint":242,"geoPoint":246,"contacts":247},"Cleveland Clinic","Cleveland","Ohio","44194",{"type":43,"coordinates":243},[244,245],-81.69541,41.4995,{"lat":245,"lon":244},[248,252],{"name":249,"role":27,"phone":250,"phoneExt":11,"email":251},"Molly Haberkorn","216-445-6434","HABERKS@ccf.org",{"name":253,"role":58,"phone":11,"phoneExt":11,"email":11},"Nicholas Austin, DO",{"facility":255,"status":36,"city":255,"state":240,"zip":256,"country":40,"countryCode":41,"cosmosGeoPoint":257,"geoPoint":261,"contacts":262},"Kettering","45429",{"type":43,"coordinates":258},[259,260],-84.16883,39.6895,{"lat":260,"lon":259},[263,267],{"name":264,"role":27,"phone":265,"phoneExt":11,"email":266},"Kathren Garber","937-395-8390","kathren.garber@ketteringhealth.org",{"name":268,"role":58,"phone":11,"phoneExt":11,"email":11},"Arif Sheikh, MD",{"facility":270,"status":36,"city":271,"state":272,"zip":273,"country":40,"countryCode":41,"cosmosGeoPoint":274,"geoPoint":278,"contacts":279},"University of Pennsylvania, Perelman School of Medicine","Philadelphia","Pennsylvania","19104",{"type":43,"coordinates":275},[276,277],-75.16362,39.95238,{"lat":277,"lon":276},[280,284],{"name":281,"role":27,"phone":282,"phoneExt":11,"email":283},"Erin Schubert","215-573-6569","Erin.schubert@pennmedicine.upenn.edu",{"name":285,"role":58,"phone":11,"phoneExt":11,"email":11},"Mark Sellmyer, MD, PhD",{"type":287,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100609678","phase-3-using-18f-fapi-pet-to-detect-metastatic-disease-in-patients-that-have-gastric-or-esophageal-cancer-100609678",false,"NCT07217704","Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [¹⁸F]FAPI-74 PET\u002FCT for the Detection of Metastatic Disease in Adults With Gastric or Esophageal Cancer","FAPI-GO","Inclusion Criteria:\n\n* Male and female adults ≥ 18 years.\n* Participants with confirmed gastric, esophageal or gastroesophageal malignancy undergoing staging evaluation for treatment planning.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Provided signed, written informed consent prior to any study-related procedures.\n* Participants are required to have a ceCT scan of chest, abdomen and pelvis as per standard clinical practice and practice guidelines either 21 days or less prior to entry or planned within 21 days of \\[¹⁸F\\]FAPI-74 administration.\n* For women who are not postmenopausal (two years of amenorrhea) or surgically sterile (absence of ovaries and\u002For uterus): agreement to use medically accepted, highly effective methods of contraception (e.g., hormonal implants, combined oral contraceptives, vasectomized partner, during the trial intervention period.\n\nExclusion Criteria:\n\n* Unequivocal evidence of metastases at the time of enrollment that would preclude surgery as a treatment option.\n* Known hypersensitivity to \\[¹⁸F\\]FAPI-74.\n* Administration of another investigational diagnostic or therapeutic product within 30 days prior to \\[¹⁸F\\]FAPI-74 administration.\n* Prior administration of a radiopharmaceutical within 10 half-lives of that product from the time of \\[¹⁸F\\]FAPI-74 administration.\n* Previous cancer (except basal cell carcinoma of the skin or in situ carcinoma of the cervix\u002Futerus (participants treated with curative intent and disease free for more than 5 years are permitted).\n* Hepatic function: T. bili \\>1.5X ULN or alk phos, ALT, or AST \\>5X ULN\n* Renal function: GFR \\\u003C 30 mL\u002Fmin\n* Pregnant or currently breast feeding (a negative pregnancy test is required in women of childbearing potential).\n* Inability to undergo the PET\u002FCT scanning procedure.\n* Inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Sarcoidosis\n* Treatment, including chemotherapy, radiation, immunotherapy or surgery for curative intent of Gastroesophageal cancers","ALL","18 Years",{"count":299,"type":300},200,"ESTIMATED","INTERVENTIONAL",[303],"PHASE3","This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \\[¹⁸F\\]FAPI-74 PET\u002FCT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \\[¹⁸F\\]FAPI-74 PET\u002FCT screening. SOC procedures and interventions will be captured during 3 months +\u002F-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \\[¹⁸F\\]FAPI-74 PET\u002FCT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \\[¹⁸F\\]FAPI-74 PET\u002FCT.",[306,307,308],"Esophageal Cancer","Gastric Cancer (GC)","Gastroesophageal Junction",[310,311,312,313,314,315],"FAP","Fibroblast Activation Protein","Fibroblast Activation Protein Inhibitor","FAPI","gastroesophageal cancer","PET","2026-06-26",{"date":318,"type":319},"2026-06-30","ACTUAL",{"date":321,"type":319},"2025-11-14",{"date":323,"type":300},"2027-08-30",{"name":5,"class":6},15]